In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms. It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
flexible doses from 200 mg to 600 mg
placebo
Research Site
Apeldoorn, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Veghel, Netherlands
To explore in patients with BPD the effect of quetiapine on psychotic-like symptoms and severity of psychiatric symptoms
Time frame: assessed at each visit for 8 weeks
To explore the effect of quetiapine on mood, anger, impulsiveness, hostility and anxiety in patients with BPD
Time frame: assessed at each visit for 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.